Drugs / PF-08653945
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07575932 | May 2026 → Aug 2027 expected | metabolic disease, obesity disorder | Pfizer | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-08653945 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07575932 ↗ |
| Route | Subcutaneous | “Participants receive subcutaneous injections of PF-08653945 + PF-08653944 or placebo.” NCT07575932 ↗ |